

# Bernd Hoppe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6281315/publications.pdf>

Version: 2024-02-01

88  
papers

4,566  
citations

94381

37  
h-index

106281

65  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3202  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. <i>Kidney International</i> , 2022, 101, 626-634.	2.6	47
2	Diet-related urine collections: assistance in categorization of hyperoxaluria. <i>Urolithiasis</i> , 2022, 50, 141-148.	1.2	3
3	Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry. <i>Kidney International Reports</i> , 2022, 7, 210-220.	0.4	19
4	Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. <i>Kidney International Reports</i> , 2022, 7, 1608-1618.	0.4	7
5	Improving Treatment Options for Primary Hyperoxaluria. <i>Drugs</i> , 2022, 82, 1077-1094.	4.9	13
6	Effects of <i>Oxalobacter formigenes</i> in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1464-1473.	0.4	24
7	Is stiripentol truly effective for treating primary hyperoxaluria?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 442-444.	1.4	10
8	Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the <i>EARLY PROTECT</i> Alport trial. <i>Clinical Genetics</i> , 2021, 99, 143-156.	1.0	7
9	Endurance-oriented training program with children and adolescents on maintenance hemodialysis to enhance dialysis efficacy <i>DiaSport</i> . <i>Pediatric Nephrology</i> , 2021, 36, 3923-3932.	0.9	2
10	A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. <i>Kidney International</i> , 2021, 100, 621-635.	2.6	26
11	New Aspects of Kidney Fibrosis—From Mechanisms of Injury to Modulation of Disease. <i>Frontiers in Medicine</i> , 2021, 8, 814497.	1.2	21
12	Endurance training during maintenance hemodialysis in pediatric and adolescent patients—theory and best practice suggestions. <i>Pediatric Nephrology</i> , 2020, 35, 595-602.	0.9	3
13	Inherited conditions resulting in nephrolithiasis. <i>Current Opinion in Pediatrics</i> , 2020, 32, 273-283.	1.0	16
14	Plasma oxalate: comparison of methodologies. <i>Urolithiasis</i> , 2020, 48, 473-480.	1.2	16
15	Examination of the eye and retinal alterations in primary hyperoxaluria type 1. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	5
16	<i>Oxalobacter formigenes</i> treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis. <i>Pediatric Nephrology</i> , 2020, 35, 1121-1124.	0.9	11
17	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. <i>Kidney International</i> , 2020, 97, 1275-1286.	2.6	94
18	Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function. <i>Pediatric Nephrology</i> , 2020, 35, 1227-1233.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study. <i>Pediatric Nephrology</i> , 2019, 34, 2591-2600.	0.9	11
20	Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. <i>Kidney International</i> , 2019, 96, 1389-1399.	2.6	61
21	Management of bone disease in cystinosis: Statement from an international conference. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 1019-1029.	1.7	39
22	The Ocular Phenotype in Primary Hyperoxaluria Type 1. <i>American Journal of Ophthalmology</i> , 2019, 206, 184-191.	1.7	21
23	Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction. <i>American Journal of Human Genetics</i> , 2019, 104, 994-1006.	2.6	47
24	Targeting kidney inflammation as a new therapy for primary hyperoxaluria?. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 908-914.	0.4	14
25	A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O85-O88.	0.6	6
26	Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 4506-4522.	3.9	54
27	Outcome of renal transplantation in small infants: a match-controlled analysis. <i>Pediatric Nephrology</i> , 2018, 33, 1057-1068.	0.9	27
28	A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. <i>Urolithiasis</i> , 2018, 46, 313-323.	1.2	83
29	Genetische Nierensteinerkrankungen. <i>Medizinische Genetik</i> , 2018, 30, 438-447.	0.1	0
30	Novel therapeutic approaches in primary hyperoxaluria. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 349-357.	1.0	35
31	Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. <i>Journal of Molecular Medicine</i> , 2018, 96, 621-630.	1.7	13
32	Update on Hereditary Kidney Stone Disease and Introduction of a New Clinical Patient Registry in Germany. <i>Frontiers in Pediatrics</i> , 2018, 6, 47.	0.9	14
33	Nephrolithiasis and Nephrocalcinosis in Childhood – Risk Factor-Related Current and Future Treatment Options. <i>Frontiers in Pediatrics</i> , 2018, 6, 98.	0.9	29
34	Metabolic profile and impact of diet in patients with primary hyperoxaluria. <i>International Urology and Nephrology</i> , 2018, 50, 1583-1589.	0.6	16
35	Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease. <i>Journal of Pediatrics</i> , 2018, 199, 22-28.e6.	0.9	39
36	Extracorporeal membrane oxygenation support in a newborn with lower urinary tract obstruction and pulmonary hypoplasia: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 210.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. <i>Pediatric Nephrology</i> , 2017, 32, 1221-1232.	0.9	14
38	Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by <i>E. coli</i> O104:H4. <i>Clinical Infectious Diseases</i> , 2017, 64, 1637-1643.	2.9	35
39	A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered <i>Oxalobacter formigenes</i> to treat primary hyperoxaluria. <i>Pediatric Nephrology</i> , 2017, 32, 781-790.	0.9	66
40	Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. <i>Pediatric Nephrology</i> , 2017, 32, 2263-2271.	0.9	22
41	Genetic Risk Factors for Idiopathic Urolithiasis: A Systematic Review of the Literature and Causal Network Analysis. <i>European Urology Focus</i> , 2017, 3, 72-81.	1.6	27
42	Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 761-768.	3.0	78
43	Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. <i>Pediatric Nephrology</i> , 2017, 32, 131-137.	0.9	29
44	Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. <i>American Journal of Nephrology</i> , 2016, 43, 293-303.	1.4	7
45	Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. <i>Pediatric Nephrology</i> , 2016, 31, 443-453.	0.9	19
46	Primary hyperoxaluria – An update. <i>Journal of Pediatric Biochemistry</i> , 2015, 04, 101-110.	0.2	0
47	Nephrocalcinosis in childhood. <i>Journal of Pediatric Biochemistry</i> , 2015, 04, 111-118.	0.2	0
48	Rationale, design and objectives of ARegPKD, a European ARPKD registry study. <i>BMC Nephrology</i> , 2015, 16, 22.	0.8	46
49	Inhomogeneous Longitudinal Cardiac Rotation and Impaired Left Ventricular Longitudinal Strain in Children and Young Adults with End-stage Renal Failure Undergoing Hemodialysis. <i>Echocardiography</i> , 2015, 32, 1250-1260.	0.3	11
50	Eculizumab in Pediatric Dense Deposit Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1773-1782.	2.2	51
51	Ultrasound-Guided Percutaneous Renal Biopsy in 295 Children and Adolescents: Role of Ultrasound and Analysis of Complications. <i>PLoS ONE</i> , 2014, 9, e114737.	1.1	37
52	Urinary excretion of calcium, magnesium, phosphate, citrate, oxalate, and uric acid by healthy schoolchildren using a 12-h collection protocol. <i>Pediatric Nephrology</i> , 2014, 29, 2065-2067.	0.9	3
53	Complement Mutations in Diacylglycerol Kinase – Associated Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1611-1619.	2.2	61
54	Combined liver – kidney transplantation for hyperoxaluria type II?. <i>Pediatric Transplantation</i> , 2014, 18, 237-239.	0.5	10

#	ARTICLE	IF	CITATIONS
55	Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2366-2375.	3.0	124
56	Vitamin B6 in Primary Hyperoxaluria I. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 468-477.	2.2	110
57	Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 117-129.	1.9	61
58	Oxabact: truly a new treatment option in patients with (primary) hyperoxaluria?. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 177-184.	0.5	1
59	Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. <i>European Journal of Human Genetics</i> , 2013, 21, 162-172.	1.4	71
60	Kidney Stones in Primary Hyperoxaluria: New Lessons Learnt. <i>PLoS ONE</i> , 2013, 8, e70617.	1.1	30
61	An update on primary hyperoxaluria. <i>Nature Reviews Nephrology</i> , 2012, 8, 467-475.	4.1	239
62	Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1729-1736.	0.4	266
63	Liver cell transplantation in severe infantile oxalosis—a potential bridging procedure to orthotopic liver transplantation?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2984-2989.	0.4	43
64	Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. <i>Pediatric Nephrology</i> , 2012, 27, 1103-1109.	0.9	71
65	Nephrocalcinosis and urolithiasis in children. <i>Kidney International</i> , 2011, 80, 1278-1291.	2.6	125
66	Reduction of Plasma Oxalate Levels by Oral Application of Oxalobacter formigenes in 2 Patients With Infantile Oxalosis. <i>American Journal of Kidney Diseases</i> , 2011, 58, 453-455.	2.1	38
67	Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3609-3615.	0.4	139
68	Cardiorespiratory capacity in children and adolescents on maintenance haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3701-3708.	0.4	16
69	History, epidemiology and regional diversities of urolithiasis. <i>Pediatric Nephrology</i> , 2010, 25, 49-59.	0.9	299
70	Diagnostic examination of the child with urolithiasis or nephrocalcinosis. <i>Pediatric Nephrology</i> , 2010, 25, 403-413.	0.9	187
71	Assessment of crystallization risk formulas in pediatric calcium stone-formers. <i>Pediatric Nephrology</i> , 2009, 24, 1997-2003.	0.9	14
72	The primary hyperoxalurias. <i>Kidney International</i> , 2009, 75, 1264-1271.	2.6	314

#	ARTICLE	IF	CITATIONS
73	Urolithiasis and Nephrocalcinosis in Childhood. , 2008, , 499-525.		38
74	Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?. Urological Research, 2005, 33, 372-375.	1.5	63
75	Absorptive Hyperoxaluria Leads to an Increased Risk for Urolithiasis or Nephrocalcinosis in Cystic Fibrosis. American Journal of Kidney Diseases, 2005, 46, 440-445.	2.1	60
76	Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention. Nephrology Dialysis Transplantation, 2004, 19, 39-42.	0.4	46
77	Adverse effects of hormone preparations and related medications used to treat disorders of bone and mineral metabolism. Pediatric Endocrinology Reviews, 2004, 2 Suppl 1, 146-52.	1.2	0
78	A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatric Nephrology, 2003, 18, 986-991.	0.9	169
79	Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney International, 2003, 63, 2194-2199.	2.6	41
80	Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Frontiers in Bioscience - Landmark, 2003, 8, e437-443.	3.0	59
81	Nephrocalcinosis in preterm infants: a single center experience. Pediatric Nephrology, 2002, 17, 264-268.	0.9	51
82	The Primary Hyperoxalurias. Journal of the American Society of Nephrology: JASN, 2001, 12, 1986-1993.	3.0	197
83	Pre-emptive liver transplantation in primary hyperoxaluria type 1: A controversial issue. Pediatric Transplantation, 2000, 4, 161-164.	0.5	20
84	Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney International, 1998, 54, 921-925.	2.6	54
85	Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography: Technical Note. Kidney International, 1998, 53, 1348-1352.	2.6	49
86	Oxalate, Citrate, and Sulfate Concentration in Human Milk Compared with Formula Preparations: Influence on Urinary Anion Excretion. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 383-386.	0.9	23
87	Urinary Calcium Oxalate Saturation in Healthy Infants and Children. Journal of Urology, 1997, 158, 557-559.	0.2	59
88	Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatric Nephrology, 1993, 7, 207-211.	0.9	123